When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
JNJ - J&J's subcutaneous daratumumab on par with IV version in multiple myeloma study
Johnson & Johnson
Genmab A/S (NASDAQ:GMAB)announces positive results from an open-label Phase 3 clinical trial, APOLLO, evaluating a subcutaneous formulation of licensor Janssen Biotech's [a unit of Johnson & Johnson (NYSE:JNJ)] Darzalex (daratumumab), combined with pomalidomide and dexamethasone (Pd) versus Pd alone in patients with relapsed/refractory multiple myeloma (MM) who have previously been treated with lenalidomide and a proteasome inhibitor.
More news on: Genmab A/S, Johnson & Johnson, Healthcare stocks news,